TSC2 and cancer: We also note that 3 of 16 angiomyolipomas from P13 had no somatic mutation findings, including two without second hit mutations in TSC2. Although these angiomyolipomas may be completely silent at the genomic level, it is also possible that the samples analyzed had a low tumor representation masking identification of both LOH and somatic mutations, or that epigenetic or other types of cancer genome variation underlie these tumors.